JPS63253013A - Melanization inhibitor - Google Patents
Melanization inhibitorInfo
- Publication number
- JPS63253013A JPS63253013A JP62086362A JP8636287A JPS63253013A JP S63253013 A JPS63253013 A JP S63253013A JP 62086362 A JP62086362 A JP 62086362A JP 8636287 A JP8636287 A JP 8636287A JP S63253013 A JPS63253013 A JP S63253013A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- melanin
- baicalein
- bicalein
- baicalin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 10
- 239000000284 extract Substances 0.000 claims abstract description 22
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 claims description 27
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 claims description 27
- 229940015301 baicalein Drugs 0.000 claims description 27
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims description 19
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims description 19
- 229960003321 baicalin Drugs 0.000 claims description 19
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims description 19
- 230000008099 melanin synthesis Effects 0.000 claims description 10
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 46
- 102000003425 Tyrosinase Human genes 0.000 abstract description 17
- 108060008724 Tyrosinase Proteins 0.000 abstract description 17
- 239000000126 substance Substances 0.000 abstract description 8
- 239000002537 cosmetic Substances 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 239000000049 pigment Substances 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 6
- 230000004913 activation Effects 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000001603 reducing effect Effects 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 239000002243 precursor Substances 0.000 abstract description 2
- 230000003405 preventing effect Effects 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract 3
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000012086 standard solution Substances 0.000 description 16
- 239000000203 mixture Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229960004441 tyrosine Drugs 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- 238000004042 decolorization Methods 0.000 description 6
- 239000002674 ointment Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 241000018646 Pinus brutia Species 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 2
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 241000207929 Scutellaria Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- -1 thiol compounds Chemical class 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- TZJALUIVHRYQQB-UHFFFAOYSA-N Icarin Chemical compound C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000006959 non-competitive inhibition Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Saccharide Compounds (AREA)
- Pyrane Compounds (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】 〔イ〕発明の目的 本発明は、メラニン生成抑制剤に関する。[Detailed description of the invention] [B] Purpose of the invention The present invention relates to a melanin production inhibitor.
(産業上の利用分野)
本発明は、例えば、化粧品や医薬品、医薬部外品などの
外用塗布料の処方中に配合すれ+4 皮膚(肌)のシ
ミとり、又はシミ防止効果が得られる。(Industrial Field of Application) The present invention can be incorporated into the formulation of external application materials such as cosmetics, pharmaceuticals, and quasi-drugs to obtain stain removal or stain prevention effects on the skin.
(従来の技術)
メラニン生成抑制剤としては、例えば、システィン、グ
ルタチオンなどのSH基製剤、アスコルビン酸、プラセ
ンター抽出エキスなどが知られてい る。(Prior Art) Known examples of melanin production inhibitors include SH group preparations such as cysteine and glutathione, ascorbic acid, and placenta extract.
本発明に用いられる主役物質ミ バイカレイン又は、バ
イカリンである。これらの物質棗 コガネバナの機中に
含まれていることが知られている。The main substance used in the present invention is baicalein or baicalin. These substances are known to be contained in the fruit of jujube and Scutellaria.
コガネバナの根It、 漢方又は日周では「オウゴン
」と呼ばれている生薬の一つである。バイカレインやバ
イカリン、あるいIL オウゴンからの抽出物の応用
に関する研究は古くから行われているが。Scutellaria root It is one of the herbal medicines called ``scutellariae'' in Chinese medicine or diurnal medicine. Research on the application of baicalein, baicalin, or IL extracts from Scutellariae has been conducted for a long time.
技術文献から、外用塗布剤への利用について調査してみ
ると1例えば、次表(第1表)に示すととくの刊行物が
ある。第1表中に(*)を附したものは1本発明者らに
係る発明である。When we researched technical literature regarding its use in topical preparations, we found some publications, for example, as shown in the following table (Table 1). Items marked with an asterisk (*) in Table 1 are inventions of the present inventors.
第1表 オウゴンに関する公知刊行物(発明が解決し
ようとする問題点)
メラニン生成抑制剤として、外用塗布を主体となし、肌
(皮膚)化粧料中に用いられる薬剤としては1例えば、
グルタチオン、システィンなどのチオール系化合物の応
用が知られている。しかし、異臭が強い上、酸化されや
すく化粧料への製剤化上に問題があった。また、アスコ
ルビン酸及びその誘導体も用いられてきたが、水溶液中
では不安定である欠点があった。Table 1 Publications related to Scutellariae (problems to be solved by the invention) As melanin production inhibitors, drugs that are mainly applied externally and used in skin (skin) cosmetics include 1, for example:
Applications of thiol compounds such as glutathione and cysteine are known. However, it has a strong off-odor and is easily oxidized, causing problems in formulating it into cosmetics. Ascorbic acid and its derivatives have also been used, but they have the disadvantage of being unstable in aqueous solutions.
一方、本発明が出発原料となすオウゴンに係る刊行物を
調査してみると1例え+f−特開昭59−73509号
、特開昭60−214721号、特開昭60−2581
04号、特開昭61−122209号には、その抽出物
を用いて、保湿性及びシミ防止効果があることが示され
ており、化粧料として用いることが開示されている。On the other hand, when we investigate the publications related to Scutellariae, which is the starting material of the present invention, we find that there are some examples:
No. 04 and JP-A-61-122209 disclose that the extract has moisturizing and stain-preventing effects, and its use as a cosmetic.
また、特開昭62−1006号には、美白的作泪につい
て、示されているが、いかなる成分によるかは開示され
てはおらず、これまで、全く不明であった。Furthermore, although JP-A-62-1006 discloses a whitening effect, it does not disclose what ingredients are used, and it has been completely unknown until now.
一方1本発明者らは、すでに、特開昭61−50918
号、特開昭61−50921号、特開昭61−1705
51号などにおいて、バイカレイン又はバイカリンなど
に関する応用について研究を行ってきた。On the other hand, the present inventors have already published Japanese Patent Application Laid-Open No. 61-50918.
No., JP-A-61-50921, JP-A-61-1705
No. 51, we have conducted research on the applications of baicalein or baicalin.
そして、今回さらに研究を続けた結果、バイカレインや
バイカリンが、メラニン生成抑制作用を有する主役物質
であることを見い出すと共に、さらに生成されたメラニ
ン色素に対し、還元脱色作用を有することを突き止める
ことが出来たのである。As a result of further research, we discovered that baicalein and baicalin are the main substances that inhibit melanin production, and also found that they have a reductive depigmenting effect on the melanin pigment produced. It was.
すなわち1本発明による物質棗 生化学的なメラニンの
生成機構の一つとして知られる。チロシナーゼの活性化
を抑制することにより有色メラニンの生成量を防ぐと共
に、出来てしまった有色メラニンに対して、これを無色
化する両作用があることがわかったのである。Namely, the substance according to the present invention is known as one of the biochemical melanin production mechanisms. It was discovered that by suppressing the activation of tyrosinase, it has the effect of both preventing the production of colored melanin and making the colored melanin that has already formed colorless.
〔口〕発明の構成
(1)バイカレイン、又は、バイカリンの単独、(2)
バイカレインとバイカリンの併用、 (3)パイカレイ
ン含有エキス、又は、バイカリン含有エキスの単独、(
4)バイカレイン含有エキスとバイカリン含有エキスの
併用、上記(1)〜(4)のいずれかを配合すること登
特徴とする、メラニン生成抑制剤にある。[mouth] Structure of the invention (1) Baicalein or baicalin alone (2)
A combination of baicalein and baicalin, (3) a picalein-containing extract, or a baicalin-containing extract alone, (
4) A melanin production inhibitor characterized by the combination of a baicalein-containing extract and a baicalin-containing extract, and the combination of any one of the above (1) to (4).
具体的には、以下に実験例等をもって詳記する。Specifically, the details will be described below with experimental examples and the like.
r実験例1」
37℃の恒温槽中で、チロシンに、検体又は標準液を加
え、さらに−チロシナーゼを20分間作用させ、生成さ
れたドーパクロムを475nmの吸光度計により測定す
る方法を採用した。Experimental Example 1 A method was adopted in which a specimen or standard solution was added to tyrosine in a constant temperature bath at 37°C, and -tyrosinase was allowed to act for 20 minutes, and the dopachrome produced was measured using an absorbance meter at 475 nm.
反応組成は1次に示すごとくである。The reaction composition is as shown in the first order.
(反応組成)
L−チロシン (0,3mg/ml) ・−==4.0
mlマツクルパイン・バッフy −(p[,5)・1.
0m1a準液又は検体・・・・・・・・・・・・・・・
・・・・・・・L、 Gm lチロシナーゼ(2500
units/ml) ・・・・・・・0.1m1(実験
に用いる検体)
バイカレイン(−丸ファルコス製)
第2表中の検体Aは、バイカレイン0.3%含有70%
エタノール溶液と1,3−ブチレングリコールの混合液
とした。(Reaction composition) L-tyrosine (0.3mg/ml) -==4.0
ml Pine pine buff y - (p[,5)・1.
0m1a semi-liquid or sample・・・・・・・・・・・・・・・
......L, Gml tyrosinase (2500
units/ml) ...0.1 ml (sample used in the experiment) Baicalein (manufactured by Maru Falcos) Specimen A in Table 2 is 70% containing 0.3% baicalein.
A mixed solution of ethanol solution and 1,3-butylene glycol was prepared.
検体Bは、検体Aと精製水の混合液とした。Sample B was a mixture of sample A and purified water.
検体Cは、検体Aと精製水の混合液とした。Sample C was a mixture of sample A and purified water.
標準液Aは、 70%エタノール溶液と1.3−ブチレ
ングリコールの混合液とした。Standard solution A was a mixture of 70% ethanol solution and 1.3-butylene glycol.
標準液Bは、標準液Aと精製水の混合液とした。Standard solution B was a mixture of standard solution A and purified water.
標準液Cは、標準液Aと精製水の混合液とした第2表
チロシナーゼ活性抑制作用
「実験例2」
前記の実験例1と同様な方法で行う。Table 2: Standard solution C is a mixture of standard solution A and purified water.
Tyrosinase activity inhibition effect "Experimental Example 2" This is carried out in the same manner as in Experimental Example 1 above.
第3表中の検体として、ノ(イカレイン50%含有エキ
スを(エタノール=1.3−ブチレングリコール:水=
5H3ニア混合液)で溶解した。As the specimen in Table 3, extract containing 50% icarein (ethanol = 1.3-butylene glycol: water =
5H3Nia mixed solution).
標準液は、エタノール=1.3−ブチレングリコール
:水== 5 :3 :’lの混合液とした。The standard solution is ethanol = 1.3-butylene glycol
:Water==5:3:'l.
第3表 チロシナーゼ活性抑制作用 [実験例3J 前記の実験例1と同様な方法で行う。Table 3 Tyrosinase activity inhibition effect [Experimental example 3J This is carried out in the same manner as in Experimental Example 1 above.
(反応組成)
L−チロシン (0,3Il1g/ml)・・・・・・
・・−・1.0mlマツクルパイン・バクファー(PH
6,5)・1.0wl標準液又は検体 ・・・・・・・
・・・・・・・・・・・・・・0.5mlチロシナーゼ
(2500units/ml) ・・・・・=0.2m
l第4表中の検体として、バイカレインをメタノール4
≠に溶解して用いた。(Reaction composition) L-tyrosine (0,3Il1g/ml)...
・・・-・1.0ml Matsukurupine Bakfur (PH
6,5)・1.0wl standard solution or sample ・・・・・・・・・
・・・・・・・・・・・・・・・0.5ml tyrosinase (2500 units/ml) ・・・・・・=0.2m
l As the sample in Table 4, baicalein was mixed with methanol 4
It was used after being dissolved in ≠.
標準液は、 メタノール溶液とした。The standard solution was a methanol solution.
第4表 チロシナーゼ活性抑制作用
実験例1〜3のチロシナーゼ活性抑制作用の成績結果を
見ると、パイ力しイン量として、約0.5mgのパイ力
しイン量を有していれば、抑制率として、約70%を示
す値となった。Table 4 Tyrosinase activity inhibitory effect Looking at the results of the tyrosinase activity inhibitory effect in Experimental Examples 1 to 3, it is found that if the amount of tyrosinase is approximately 0.5 mg, the inhibition rate is As a result, the value was approximately 70%.
r実験N4J
37℃の恒温槽中で、チロシンに、チロシナーゼを20
分間作用させることによりドーパクロムが生成される。r Experiment N4J In a constant temperature bath at 37°C, add 20% of tyrosine and tyrosinase.
Dopachrome is produced by allowing it to act for minutes.
そこで1次に、検体又は標準液を加え、1分後、475
nmの吸光度計により測定する方法を採用した。Therefore, the sample or standard solution was added as a first step, and after 1 minute, 475
A method of measurement using a nm absorbance meter was adopted.
(反応組成)
L−チロジ:/ (0,3tH/wrl) ・・・・
・、・・・・・A、0taLマツクルパイン・バッファ
ー(pi(G、 S) ・1.01al標準液又は検体
・・・・・・・・・・・・・・・・・・・・・1.0
mlチロシナーゼ(2500unHs/ml) ==・
・・O,1ml第5表中の検体として、バイカシイン5
0%含有エキスを(エタノール=1,3−ブチレングリ
ゴール:水=5:3ニア混合液)で溶解した。(Reaction composition) L-Tyrodi: / (0.3tH/wrl) ・・・・・
・・・・・・・A, 0taL pine pine buffer (pi(G, S) ・1.01al standard solution or sample ・・・・・・・・・・・・・・・・・・・・・1 .0
ml tyrosinase (2500unHs/ml) ==・
...O, 1ml As the sample in Table 5, baikasiin 5
The extract containing 0% was dissolved in (ethanol = 1,3-butylene glycol: water = 5:3 mixed solution).
標準液は、エタノール : 1.3−ブチレングリコー
ル:水= 5 :3 ニアの混合液とした。The standard solution was a mixture of ethanol:1,3-butylene glycol:water=5:3.
第5表 還元脱色作用 [実験例5」 前記に記載した実験例4と同様な方法で行う。Table 5 Reductive decolorization effect [Experiment example 5] It is carried out in the same manner as in Experimental Example 4 described above.
尚、第6表中の検体Aとは、バイカレインをメタノール
#捲に溶解して用いた。In addition, sample A in Table 6 was prepared by dissolving baicalein in methanol.
検体Bとは、バイカシ4250%含有エキスをメタノー
ル量量に溶解して用いた。Specimen B was an extract containing 4250% Baikasi dissolved in methanol.
標準液Aは、 メタノール溶液とした。Standard solution A was a methanol solution.
標準液Bは、 メタノール溶液とした。Standard solution B was a methanol solution.
第6表 還元脱色作用
実験例4〜5の還元脱色作用は、いわゆる、チロシンが
チロシナーゼにより、メラニン重合体となる反応途中で
あるドーパクロム(赤色〜褐色を呈する)を生成した後
、このドーパクロムを還元脱色する比率を求めたもので
ある。Table 6 Reductive Decolorization Effect The reductive decolorization effect in Experimental Examples 4 to 5 is the reaction of tyrosine to melanin polymer, which is produced by dopachrome (which exhibits a red to brown color), and then this dopachrome is reduced. The decolorization ratio was determined.
還元脱色率としては、それほど、高い値ではないが、
ドーパ−クロムが、さらに、進行してメラニン重合体と
なった時点でも、メラニン重合体を脱色することがうか
がえた。Although the reduction decolorization rate is not that high,
It was found that Doperchrome decolorizes the melanin polymer even when it has further progressed to become the melanin polymer.
「実験例6」
37°Cの恒温槽中で、チロシンに、チロシナーゼを、
10時間以上反応させることによって、メラニンの沈殿
物が生成されてくる。ところが、この反応組成液中に、
バイカレインを添加すると。"Experimental Example 6" In a constant temperature bath at 37°C, add tyrosine to tyrosinase.
By reacting for 10 hours or more, a melanin precipitate is generated. However, in this reaction composition,
When baicalein is added.
沈殿物(メラニン重合体)を生成しないことが確認され
た。第1図は1両溶液を、l Om 1容器のビーカー
に入れ、その状悪な示すものであるが。It was confirmed that no precipitate (melanin polymer) was generated. Figure 1 shows the poor condition of both solutions put into a beaker containing 1 Om 1 container.
これは、直接的に肉眼でも確認出来る。尚、反応組成は
1次に示すごとくである。This can be confirmed directly with the naked eye. Incidentally, the reaction composition is as shown in the first order.
L−チロシン (0,3mg/ml) ・−・−・−=
−・1.onlマツクルパイン・バッファー(PH6,
5)・1. O+al検体又は標準液(メタノール溶液
)・・・・0.5腸1を使用。L-tyrosine (0.3mg/ml) ・−・−・−=
-・1. onl pine curpine buffer (PH6,
5)・1. O+al sample or standard solution (methanol solution)...0.5 intestine 1 was used.
「実験例7」
健康な男子を対象として選び、その背部の皮膚の左右に
、大きな厚みのある黒色布を用いて、背部の左右対称の
位置に光線が直接当るように、直径3cmの円形の穴を
2カ所設置し、あらかじめ被覆しておく。"Experiment Example 7" A healthy boy was selected as the subject, and a large thick black cloth was placed on the left and right sides of the skin on his back. Install two holes and cover them in advance.
次に、紫外線(東芝製蛍光ランプ: FL−20SE
及びFL−20BLB)を、それぞれ3燈並列に接続し
、背部皮膚上から、約15cmの距離から、一定時間照
射して、これに対する塗布効果を見ることにした。Next, ultraviolet light (Toshiba fluorescent lamp: FL-20SE
and FL-20BLB) were connected in parallel with three lights each, and irradiated from a distance of about 15 cm from the back skin for a certain period of time to see the effect of application.
つまり、人工的に黒化形成のステップである。In other words, it is a step of artificially forming darkening.
紅斑を作り、これによって形成される皮膚の基底層にあ
るメラノサイトによって生成されるメラニンの色素の表
皮層への移行に伴う皮膚の色調変化を、無照射区の皮膚
の色と、肉眼的観察によって対比し、評価する方法を採
用した。Changes in skin tone due to the transfer of melanin pigment produced by melanocytes in the basal layer of the skin to the epidermal layer, which creates erythema, can be observed by visual observation and skin color in non-irradiated areas. A method of comparison and evaluation was adopted.
塗布試料は1日本薬局法に定める親木軟膏の処方に準拠
して、バイカレイン(−丸ファルコス1り0.3%を配
合したものを用いた。塗布は1日2〜3回となし、塗布
時間帯は特に指定せず、おおむね朝と晩を必須条件とし
て、40日間の連続塗布により行なった。The application sample used was one containing 0.3% of baicalein (-Maru Falcos 1) in accordance with the prescription for parent tree ointment stipulated in the Japanese Pharmacy Law.It was applied 2 to 3 times a day. The time of day was not specified, and the application was carried out continuously for 40 days, with the essential conditions being generally in the morning and in the evening.
塗布部は、背部照射部位の左側に、バイカレインを添加
した軟膏を、右側に無添加軟膏を用いて実施した。The ointment containing baicalein was applied to the left side of the back irradiation site, and the ointment without additives was applied to the right side.
その成績結果L 第7表に示すごとく肌に対する黒化
形成を抑制することがわかる。As shown in Table 7 of the results, it can be seen that the formation of darkening on the skin is suppressed.
尚、紫外線の波長域! 使用光源から、270〜32
0 n m、 及び320〜400nmの間にある。In addition, the wavelength range of ultraviolet rays! From the light source used, 270-32
0 nm, and between 320 and 400 nm.
つまり、紫外線照射後に形成される紅斑の状態に対し、
ただちに塗布を続けることによって、背部の左右の黒化
(黒色メラニン色素)が、いかに抑制できるか、無添加
軟膏と対比して経過を観察したのが第7表である。In other words, for the erythema that forms after UV irradiation,
Table 7 shows how the blackening (black melanin pigment) on the left and right sides of the back can be suppressed by continuing to apply the ointment immediately, in comparison with the additive-free ointment.
第7表 皮膚黒色メラニン色素生成抑制効果前記の実験
例1〜7において国 バイカレインを用いて行ったが、
糖が結合した状態にあるノ(イカリンについても、同様
の作用を示す、又、)くイカレインやバイカリンを高含
有するところの抽出物にあっても、同様な作用が認めら
れる。Table 7 Skin black melanin pigment production inhibitory effect In the above experimental examples 1 to 7, baicalein was used.
Icarin, which has sugars bound to it, also exhibits a similar effect, and extracts containing high amounts of icarein and baicalin also exhibit similar effects.
但し、バイカリンで!瓢 その作用はバイカレインに較
べ、遅効性である。つまり、糖が切断されたアグリコン
となって、はじめてメラニン生成の抑制作用を発揮する
ことが特長である。したがって、速効性を得るには、バ
イカレインが有利であり、遅効性とするには、そのアグ
リコンであるバイカリンを用い、又1両機能を保持させ
るには。However, with baicalin! Gourd Its action is slower than that of baicalein. In other words, it is unique in that it only exerts its effect on suppressing melanin production after the sugar is cleaved into aglycone. Therefore, to obtain rapid action, baicalein is advantageous, and to obtain slow action, use its aglycone baicalin, and to retain both functions.
併用することが良い、バイカレインに結合した糖は、生
体内中のグルクロニダーゼ、あるいは、熱処理などによ
りて切断され、あるいは苛酷な紫外線等に長時間暴露さ
れることなどによっても、バイカリンへと反応が進む、
したがって、例えば。The sugar bound to baicalein, which is best used in combination, is cleaved by glucuronidase in the body, heat treatment, etc., or the reaction progresses to baicalin by long-term exposure to harsh ultraviolet rays, etc. ,
Therefore, for example.
肌用のクリームや乳液など、加熱処理が加わるような化
粧料などでは、バイカリンを処方中に用いることも良い
。Baicalin can also be used in the formulation of cosmetics that undergo heat treatment, such as skin creams and emulsions.
(ハ)発明の効果
本発明は、バイカレイン又は、バイカリンをメラニン生
成抑制剤として用いる。新規な利用方法に関するもので
あるが、とくに純品を用いる必要はなく、オウゴンから
抽出されたエキスの内、バイカレイン又は、バイカリン
を含有する抽出エキスを用いても良い。(c) Effects of the Invention The present invention uses baicalein or baicalin as a melanin production inhibitor. Although it is related to a new method of use, it is not necessary to use a pure product, and an extract containing baicalein or baicalin among extracts extracted from Scutellariae may be used.
次に、本発明による効果について、その作用機序を説明
すれば、第2図に示すととくの生化学的反応機構からは
、 (A)とCB)に係わるチロシナーゼの活性化を抑
制する一方、同時に、生成された。有色物質(メラニン
前駆物質)〔3]〜〔5]さらに、 〔6〕で示される
有色メラニン色素については、これを還元することによ
って、jA色の物質となす1両作用があることである。Next, to explain the mechanism of action of the effects of the present invention, from the biochemical reaction mechanism shown in Figure 2, it is possible to suppress the activation of tyrosinase related to (A) and CB). , at the same time, was generated. Colored Substances (Melanin Precursors) [3] to [5] Furthermore, the colored melanin pigment shown in [6] has both effects as a jA color substance by reducing it.
すなわち、実験例1〜3で示したチロシナーゼ活性抑制
作用機序について、考案を加えてみると。That is, if we add a new idea to the mechanism of tyrosinase activity inhibition shown in Experimental Examples 1 to 3.
チロシナーゼ酵素タンパクへの結合(拮抗阻害、非拮抗
阻害を含む)による抑制作用と、酵素の活性化に必要な
金属(鉄と銅)とキレート化合物を作り一*素反応に必
要な鉄イオン、銅イオンを取り、除き、酵素反応を抑制
させる作用(チロシナーゼ活性抑制作用)があると考え
られる。It has an inhibitory effect by binding to the tyrosinase enzyme protein (including competitive inhibition and non-competitive inhibition), and produces chelate compounds with the metals (iron and copper) necessary for the activation of the enzyme, and iron ions and copper necessary for the 1*element reaction. It is thought to have the effect of removing ions and suppressing enzyme reactions (tyrosinase activity suppressing effect).
又、実験例4〜7で示した還元脱色作用は、すでに、生
成されてしま9たドーパクロム(赤色〜褐色を呈する)
を、還元脱色することであり、このために、*色メラニ
ンの生成は抑制される。In addition, the reductive decolorization effect shown in Experimental Examples 4 to 7 is due to the already generated dopachrome (which exhibits a red to brown color).
This is to reduce and decolorize the melanin, and for this reason, the production of *color melanin is suppressed.
そして、ドーパクロムより、さらに反応が進行し、メラ
ニンを生成しても、第1図に示すととくの還元脱色作用
を発揮することとなる。Even if the reaction proceeds further than dopachrome and melanin is produced, it exhibits a special reductive decolorizing effect as shown in FIG.
実験例1〜7で示した成績結果より1本発明は、チロシ
ナーゼ活性抑制作用な墳するばかりでするところのメラ
ニン生成抑制剤である。From the results shown in Experimental Examples 1 to 7, the present invention is a melanin production inhibitor that has an inhibitory effect on tyrosinase activity.
このように、メラニン、ドーパクロム、ドーパキノンな
どの生成する前段階と、生成された後の段階を抑えるこ
との出来る物質は、きわめて限られたものしか知られて
おらず1本発明は化粧料等への利用に当って望ましいも
のと考えられる。As described above, only a very limited number of substances are known that can suppress the stages before and after the production of melanin, dopachrome, dopaquinone, etc., and the present invention is useful for cosmetics, etc. This is considered desirable when using
第1図は、メラニン沈澱状態を示す、Aは、標準液、B
は、バイカレインを添加したときの状態て有色メラニン
が確認できないことを示す。
尚、Bに示す、バイカレイン量は、0.1mgを添加し
たときの状態である。
第2図は、メラニンが生成する化学的反応機構である。
式である。
第4図は、バイカレイン(CI%H1゜OS)の構造式
である。Figure 1 shows the state of melanin precipitation, A is the standard solution, B
indicates that colored melanin cannot be observed when baicalein is added. Incidentally, the amount of baicalein shown in B is the state when 0.1 mg was added. Figure 2 shows the chemical reaction mechanism by which melanin is produced. It is a formula. FIG. 4 is the structural formula of baicalein (CI%H1°OS).
Claims (1)
イカレインとバイカリンの併用、(3)バイカレイン含
有エキス、又は、バイカリン含有エキスの単独、(4)
バイカレイン含有エキスとバイカリン含有エキスの併用
、上記(1)〜(4)の内、そのいずれかの成分を配合
することを特徴とする、メラニン生成抑制剤。[Scope of Claims] [1] (1) Baicalein or baicalin alone, (2) a combination of baicalein and baicalin, (3) baicalein-containing extract or baicalin-containing extract alone, (4)
A melanin production inhibitor characterized by a combination of a baicalein-containing extract and a baicalin-containing extract, and any one of the components (1) to (4) above.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62086362A JPS63253013A (en) | 1987-04-08 | 1987-04-08 | Melanization inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62086362A JPS63253013A (en) | 1987-04-08 | 1987-04-08 | Melanization inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS63253013A true JPS63253013A (en) | 1988-10-20 |
Family
ID=13884772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP62086362A Pending JPS63253013A (en) | 1987-04-08 | 1987-04-08 | Melanization inhibitor |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS63253013A (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06107532A (en) * | 1992-09-28 | 1994-04-19 | Kao Corp | Cosmetic for fair skin and beauty |
JPH07187988A (en) * | 1993-12-27 | 1995-07-25 | Nagase & Co Ltd | Melanism inhibitor, its production and skin-beautifying containing the same cosmetic |
KR100495454B1 (en) * | 2002-03-27 | 2005-06-14 | 주식회사 코리아나화장품 | Cosmetic Compositions for Skin-Whitening Comprising Phytolight as Active Ingredient |
JP2006316029A (en) * | 2005-05-16 | 2006-11-24 | Maruzen Pharmaceut Co Ltd | Endothelin-1 production inhibitor and melanin production inhibitor |
JP2008528640A (en) * | 2005-02-01 | 2008-07-31 | シャンハイ グルアォリ バイオファーマシューティカルズ カンパニー リミテッド | Antitumor synergistic pharmaceutical composition of baicalein and baicalin |
JP2009091355A (en) * | 2007-09-19 | 2009-04-30 | Noevir Co Ltd | Humectant, anti-aging agent, antioxidant agent, immunostimulator, skin-lightening agent, external preparation for skin and functional oral composition |
JP2010083804A (en) * | 2008-09-30 | 2010-04-15 | Saishunkan Seiyakusho:Kk | Skin lightening cosmetic |
US7994141B2 (en) * | 2006-12-15 | 2011-08-09 | Biospectrum, Inc. | Compositions comprising compounds of natural origin for damaged skin |
JP2014058494A (en) * | 2012-08-20 | 2014-04-03 | Beatrix Inc | Tear stain or slaver stain inhibitor |
JP2017105843A (en) * | 2011-07-07 | 2017-06-15 | ロレアル | Light protective compositions |
JP2017521411A (en) * | 2014-06-30 | 2017-08-03 | 株式会社アモーレパシフィックAmorepacific Corporation | Whitening composition containing Scutellaria alpina extract |
EP4321148A1 (en) * | 2022-08-10 | 2024-02-14 | CUTANEON - Skin & Hair Innovations GmbH | Active agent modulating the activity of an ion channel for use in regulation of skin pigmentation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5973509A (en) * | 1982-10-18 | 1984-04-25 | Osaka Chem Lab | Cosmetic composition containing ogon |
JPS6150918A (en) * | 1984-08-20 | 1986-03-13 | Ichimaru Fuarukosu Kk | Liquid composition containing baicalin or baicalein and external drug for skin or skin cosmetic containing same |
-
1987
- 1987-04-08 JP JP62086362A patent/JPS63253013A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5973509A (en) * | 1982-10-18 | 1984-04-25 | Osaka Chem Lab | Cosmetic composition containing ogon |
JPS6150918A (en) * | 1984-08-20 | 1986-03-13 | Ichimaru Fuarukosu Kk | Liquid composition containing baicalin or baicalein and external drug for skin or skin cosmetic containing same |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06107532A (en) * | 1992-09-28 | 1994-04-19 | Kao Corp | Cosmetic for fair skin and beauty |
JPH07187988A (en) * | 1993-12-27 | 1995-07-25 | Nagase & Co Ltd | Melanism inhibitor, its production and skin-beautifying containing the same cosmetic |
KR100495454B1 (en) * | 2002-03-27 | 2005-06-14 | 주식회사 코리아나화장품 | Cosmetic Compositions for Skin-Whitening Comprising Phytolight as Active Ingredient |
JP2008528640A (en) * | 2005-02-01 | 2008-07-31 | シャンハイ グルアォリ バイオファーマシューティカルズ カンパニー リミテッド | Antitumor synergistic pharmaceutical composition of baicalein and baicalin |
JP2006316029A (en) * | 2005-05-16 | 2006-11-24 | Maruzen Pharmaceut Co Ltd | Endothelin-1 production inhibitor and melanin production inhibitor |
US7994141B2 (en) * | 2006-12-15 | 2011-08-09 | Biospectrum, Inc. | Compositions comprising compounds of natural origin for damaged skin |
JP2009091355A (en) * | 2007-09-19 | 2009-04-30 | Noevir Co Ltd | Humectant, anti-aging agent, antioxidant agent, immunostimulator, skin-lightening agent, external preparation for skin and functional oral composition |
JP2010083804A (en) * | 2008-09-30 | 2010-04-15 | Saishunkan Seiyakusho:Kk | Skin lightening cosmetic |
JP2017105843A (en) * | 2011-07-07 | 2017-06-15 | ロレアル | Light protective compositions |
JP2019059791A (en) * | 2011-07-07 | 2019-04-18 | ロレアル | Light protective compositions |
JP2014058494A (en) * | 2012-08-20 | 2014-04-03 | Beatrix Inc | Tear stain or slaver stain inhibitor |
JP2017521411A (en) * | 2014-06-30 | 2017-08-03 | 株式会社アモーレパシフィックAmorepacific Corporation | Whitening composition containing Scutellaria alpina extract |
EP4321148A1 (en) * | 2022-08-10 | 2024-02-14 | CUTANEON - Skin & Hair Innovations GmbH | Active agent modulating the activity of an ion channel for use in regulation of skin pigmentation |
WO2024033113A1 (en) * | 2022-08-10 | 2024-02-15 | Cutaneon - Skin & Hair Innovations Gmbh | Active agent modulating the activity of an ion channel for use in regulation of skin pigmentation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS63253013A (en) | Melanization inhibitor | |
JPS6019885B2 (en) | Whitening cosmetics containing isoflavone compounds | |
WO2010053340A2 (en) | Skin-whitening composition | |
JP4381382B2 (en) | Topical depigmentation formulation containing an extract of Verisperennis | |
EP2098228A1 (en) | Antiinflammatory agent comprising 2-aminophenol or derivative thereof as active ingredient | |
JPS63316711A (en) | Beautifying and whitening cosmetic | |
JPH01311011A (en) | Melanization inhibitory drug for external use | |
JP2004517857A (en) | Whitening agent containing arbutin and glucosidase as active ingredients | |
KR100419527B1 (en) | Use of sulfites and metabisulfites for manufacturing cosmetic or pharmaceutical compositions, notably in dermatology, with melanogenesis-inhibiting effect or with depigmenting activity | |
KR100538866B1 (en) | Method of synthesis of derivatives of aloesin | |
KR100447441B1 (en) | Skin whitening agent containing bird's nest extract as tyrosinase inhibiting agent as main component and albutin or kojic acid as auxiliary component | |
JPS62286909A (en) | Tyrosinase inhibitor | |
JP3120086B2 (en) | Hair cosmetics for prevention of gray hair and blackening of gray hair | |
JP3120087B2 (en) | Hair cosmetics for prevention of gray hair and blackening of gray hair | |
JPH01207225A (en) | Cosmetic for hair | |
JPH0867616A (en) | Cosmetic | |
JPH01305025A (en) | Agent for suppressing formation of enzyme | |
JPH10279468A (en) | Skin preparation for external use | |
KR100954984B1 (en) | Anti-inflammatory cosmetic compositions containing of herb medicines | |
JPH06145040A (en) | Melanogenesis-suppressing agent | |
KR102648506B1 (en) | Cosmetic composition containing mangrove root and guaajava leaf | |
JP5996706B1 (en) | Tsurmurasaki extract and its use for whitening and sun protection | |
JPH02193918A (en) | Agent for suppressing formation of enzyme | |
KR20100016815A (en) | Cosmetic compositions for skin whitening containing sedum sarmentosum extract and arbutin | |
JPH04235113A (en) | Skin-beautifying cosmetic |